The proxy fight outcome is binary: a DOMA win could trigger a sale process or cost cuts, while a Pacira win maintains current strategy. The cross-filing amplifier suggests this activist context increases expected stock movement. Monitor vote tallies and any further 13D filings from DOMA. The June 9 meeting date is the key catalyst.
Price Chart
Executive Summary
Pacira BioSciences issued a press release urging stockholders to vote for its board nominees at the June 9 annual meeting, countering activist DOMA Perpetual Capital Management. The company highlighted record 2025 revenue of $726.4M, 79.4% GAAP gross margins, and a $200M buyback return since April 2025, while criticizing DOMA's plan to cut costs, halt pipeline development, and pursue a sale. This is an escalating proxy fight with material implications for strategic direction.
Key Financial Metrics
Key Facts
- Pacira achieved record total revenue of $726.4M in 2025 with GAAP gross margins of 79.4% and non-GAAP gross margins of 81.2%.
- Q1 2026 revenue: EXPAREL $143.3M (+5% YoY), ZILRETTA $26.8M (+15% YoY), iovera° $6.2M (+21% YoY).
- Company has returned $200M to stockholders since April 2025 under a $300M share repurchase program.
- Pacira reached a volume-limited settlement in EXPAREL patent litigation securing exclusivity through 2030.
- Activist DOMA Perpetual Capital Management seeks to replace three directors, cut costs, discontinue pipeline, replace CEO, and initiate a sale process.
- Annual meeting scheduled for June 9, 2026; record date April 22, 2026.
- Pacira's board would be 89% independent with average tenure of ~4.6 years after the meeting.
- Cross-filing context: press-8k-context + press-activist-context is an amplifier (PMI=2.28, q=0.000, n=3144).
Financial Impact
Record revenue of $726.4M in 2025; Q1 2026 revenue growth across all three products (5-21% YoY); $200M returned via buybacks; $300M buyback program authorized.
Risk Factors
- Activist victory could lead to a fire sale at potentially depressed valuation.
- DOMA's proposed cost cuts may harm revenue growth and pipeline prospects.
- Patent litigation settlement is volume-limited, leaving some uncertainty on exclusivity beyond 2030.
- Historical performance on PCRX shows mixed T+20 outcomes with negative alpha vs SPY (-5.15% avg).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298294 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $25.58 $26.60 | ▲ +3.99% | ▲ +3.39% | $25.18 (−1.56%) |
Jul 22, 2026 10w ago | Press Release | $25.59 $24.36 | ▼ −4.81% | ▼ −7.70% | $25.18 (−1.60%) |
Jun 30, 2026 13w ago | 8-K | $25.37 $26.47 | ▲ +4.34% | ▲ +5.36% | $25.18 (−0.75%) |
Jun 13, 2026 15w ago | Insider Cluster | $22.74 $25.54 | ▲ +12.31% | ▲ +13.06% | $25.18 (+10.73%) |
Jun 4, 2026 17w ago | DEFA14A | $22.75 $25.59 | ▲ +12.48% | ▲ +10.62% | $25.18 (+10.68%) |
Jun 4, 2026 17w ago | 144 | $22.67 $25.39 | ▲ +12.00% | ▲ +13.37% | $25.18 (+11.07%) |
Jun 1, 2026 17w ago | DEFA14A | $22.25 $25.03 | ▲ +12.49% | ▲ +14.06% | $25.18 (+13.17%) |
May 27, 2026 18w ago | DEFA14A | $23.68 $25.24 | ▲ +6.59% | ▲ +9.73% | $25.18 (+6.33%) |
May 26, 2026 18w ago | DEFA14A | $24.04 $24.37 | ▲ +1.37% | ▲ +3.27% | $25.18 (+4.74%) |
May 20, 2026 19w ago | DEFA14A | $23.48 $22.72 | ▼ −3.24% | ▼ −3.57% | $25.18 (+7.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access